JP6866164B2 - 固形生体腫瘤の空間的分子プロファイリングおよびプロファイルの保存 - Google Patents
固形生体腫瘤の空間的分子プロファイリングおよびプロファイルの保存 Download PDFInfo
- Publication number
- JP6866164B2 JP6866164B2 JP2016575441A JP2016575441A JP6866164B2 JP 6866164 B2 JP6866164 B2 JP 6866164B2 JP 2016575441 A JP2016575441 A JP 2016575441A JP 2016575441 A JP2016575441 A JP 2016575441A JP 6866164 B2 JP6866164 B2 JP 6866164B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- fta
- biological
- mass
- exposed portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007787 solid Substances 0.000 title claims description 18
- 239000002028 Biomass Substances 0.000 title claims 2
- 238000004321 preservation Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 238000003556 assay Methods 0.000 claims description 11
- 239000012620 biological material Substances 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000003945 anionic surfactant Substances 0.000 claims description 3
- 230000003196 chaotropic effect Effects 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000011529 RT qPCR Methods 0.000 claims description 2
- 238000011901 isothermal amplification Methods 0.000 claims description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 claims description 2
- 238000004166 bioassay Methods 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 101150055229 FTA gene Proteins 0.000 description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 21
- 239000000523 sample Substances 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 16
- 102000016911 Deoxyribonucleases Human genes 0.000 description 15
- 108010053770 Deoxyribonucleases Proteins 0.000 description 15
- 102000006382 Ribonucleases Human genes 0.000 description 14
- 108010083644 Ribonucleases Proteins 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 4
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 4
- 102100031893 Nanos homolog 3 Human genes 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229920003043 Cellulose fiber Polymers 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000000954 titration curve Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000723833 Homo sapiens Zinc finger E-box-binding homeobox 2 Proteins 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 102000018334 Lysophosphatidic acid receptor EDG-2 Human genes 0.000 description 1
- 108050007477 Lysophosphatidic acid receptor EDG-2 Proteins 0.000 description 1
- 101150107698 MYH6 gene Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 201000011024 colonic benign neoplasm Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/2813—Producing thin layers of samples on a substrate, e.g. smearing, spinning-on
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/16—Reagents, handling or storing thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/2813—Producing thin layers of samples on a substrate, e.g. smearing, spinning-on
- G01N2001/282—Producing thin layers of samples on a substrate, e.g. smearing, spinning-on with mapping; Identification of areas; Spatial correlated pattern
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Description
1)病理学者または研究者は患者または動物から腫瘍を摘出後、腫瘍の横断面を滑らかに切断して腫瘍を横切する。
1)試料が十分規定された領域から採取可能なように、腫瘍の二次元「空間的マップ」を維持する能力。
c57BL/6マウスおよびNOS3ヌルマウス(バックグラウンド129/B6)由来のネズミ組織を、Whatman Incから販売されているFTAクラシックマイクロカード、indicatingマイクロカードおよびFTA eluteマイクロカードを含むいくつかの異なる固体支持媒体に適用した。これらのマウスを安楽死させ、解剖して臓器(血液、心臓、脳、肺、肝臓および腎臓)を収集した。臓器を、2層の上記のさまざまなFTAマトリックスの間に「サンドイッチ」した。それぞれの化学的にコーティングされたセルロースマトリックスにはめ込まれた組織に滅菌ピペットにより圧力を印加した。組織ホモジネート用に、およそ5gの組織をプラスチックダウンス型ホモジナイザーを使用して、1.5mlのマイクロチューブにおいて処理し、次いで適切なFTAマトリックスに適用した。適用後、すべての試料を2時間風乾させ、その後密閉されたポーチにおいて乾燥剤と一緒に保存した。場合により、試料は処理まで最大2ヶ月保存した。
Harrisの使い捨てマイクロパンチ(直径1.2mmまたは3mm)を使用して、FTAマイクロカードおよびFTA eluteマイクロカードから乾燥組織試料を、それぞれパンチされたディスクの形態で切り取った。試料ディスクを乾燥試料の中心から切り取り、清潔なDNase非含有1.5ml微小遠心管に入れた。ゲノムDNAをFTAカードおよびFTA eluteカードから抽出するために、標準的精製手順を製造業者の使用説明書にしたがって続けた。
FTAマトリックスに保存されたDNAから遺伝子型変異体を識別する能力を例示するために、ある領域のPCR増幅をWTおよびトランスジェニック(NOS3ヌル、遺伝子ノックアウト)マウスに実施した。
組織試料を上記のFTAカードに適用した。FTA試料パンチを切り取り、RNAを下記のGE Healthcare illustra RNAspinキットを使用して単離した。RNAの定量を、ABI7900リアルタイムPCRシステムで市販のmRNA定量キットを利用して表2に詳細に示すように実施した。
2次元(2D)腫瘍マッピングを使用して、腫瘍の辺縁において主に発生する上皮間葉転換(Epithelial−to−Mesenchymal Transistion)(EMT)に関係するマーカーなどの腫瘍浸潤の分子マーカーを分析することができる。下記の表3は、腫瘍の浸潤性を決定するために使用可能な適切な遺伝子マーカーの例を記載している。
Horak,C.E.,J.H.Lee,et al.(2007).「N m 2 3 −H l suppresses tumor cell motility by down−regulating the lysophosphatidic acid receptor EDG2.」Cancer Res 67(15):7238−7246
Bloomston,M.,A.Shafii,et al.(2002).「TIMP−1 overexpression in pancreatic cancer attenuates tumor growth,decreases implantation and metastasis,and inhibits angiogenesis.」J Surg Res 102(1):39−44
Zhang,L.,L.Zhao,et al.(2010)「Inhibition of tumor growth and induction of apoptosis in prostate cancer cell lines by overexpression of tissue inhibitor of matrix metalloproteinase−3.」Cancer Gene Ther.17(3):171−9。
タンパク質および酵素試験を、完全に構成されたDNaseおよびRNase Contamination Kits(DNaseおよびRNase Alert QC Systems、カタログコードAM1970およびAM1966、Life Technologies)を用いて製造業者の使用説明書に従って実施した。
組み換え体IL−2±キャリア(R&D Systems;それぞれカタログ番号202−IL−CF−10μg;ロットAE4309112およびカタログ番号202−IL−10μg;ロットAE4309081)を、カルシウムおよびマグネシウムを含まないダルベッコPBS(PAA;カタログ番号H15−002、ロットH00208−0673)、EDTA−抗凝固処理ヒト、ウサギまたはウマ血液(TCS Biosciences)のいずれかに50pgまたは100pg/μlで溶解した。
11 底部
12 直立スパイク、反転インプリント、保持手段
20 腫瘍、横断切片
22 辺縁部
24 内部領域
30 支持体
32 印刷された格子パターン
32’ 画像に重ねられた格子パターン
Claims (8)
- 生体物質から形成される生体腫瘤の空間的分子プロファイリングを取り込む方法であって、
a)横切された生体腫瘤、例えば腫瘍の露出した部分の面積と少なくとも同じ面積の固体支持体を提供するステップ、
b)生体物質を前記腫瘤の露出した部分から前記支持体に転写して、前記腫瘤の露出した部分に存在する生体物質の2次元インプリントを前記支持体に提供するステップ、
c)前記腫瘤の露出した部分の空間的分子プロファイルを決定するために、前記インプリントのさまざまな所定の位置から前記転写された生体物質の生物学的アッセイを複数回実施するステップ
を含み、前記固体支持体表面に、弱塩基、キレート化剤、陰イオン界面活性剤および/またはカオトロピック剤を含む化学物質が含浸されており、
前記転写された生体物質が、RNAを含む、方法。 - 前記生体物質を転写するステップが、前記腫瘤の露出した部分と前記支持体とを接触させるステップを含む、請求項1に記載の方法。
- 前記腫瘤の露出した部分が、前記腫瘤の辺縁部を含み、更に、前記腫瘤の概ね中心部分を含む、または含まない、請求項1または2に記載の方法。
- 前記複数回のアッセイが、PCR、逆転写酵素PCR、定量的リアルタイムPCR、等温増幅などの核酸増幅を含む、請求項1、2または3のいずれか1項に記載の方法。
- 本明細書の表3に記号化された遺伝子の1または複数の存在を決定するさらなるステップを含む、請求項1乃至4のいずれか1項に記載の方法。
- 横切された生体腫瘤を画像化するさらなるステップを含む、請求項1乃至5のいずれか1項に記載の方法。
- 前記固体支持体に基準格子を提供するステップ、および前記画像に同様の格子を重ね合わせるステップを含む、請求項6に記載の方法。
- 腫瘍などの生体腫瘤の少なくとも一部から生体物質の空間的プロファイルを取り込むためのキットであって、
前記腫瘤と接触させるための、前記腫瘤の一部の面積と少なくとも等しい面積の固体支持体、および目的の核酸の増幅の開始に適切なプライマーを含む乾燥試薬を含み、
前記固体支持体表面に、弱塩基、キレート化剤、陰イオン界面活性剤および/またはカオトロピック剤を含む化学物質が含浸されており、
前記生体物質が、RNAを含む、キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1411624.8A GB201411624D0 (en) | 2014-06-30 | 2014-06-30 | Spatial molecular profiling of solid biological masses and profile storage |
GB1411624.8 | 2014-06-30 | ||
PCT/EP2015/064037 WO2016001006A1 (en) | 2014-06-30 | 2015-06-23 | Spatial molecular profiling of solid biological masses and profile storage |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017521065A JP2017521065A (ja) | 2017-08-03 |
JP6866164B2 true JP6866164B2 (ja) | 2021-04-28 |
Family
ID=51410374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016575441A Active JP6866164B2 (ja) | 2014-06-30 | 2015-06-23 | 固形生体腫瘤の空間的分子プロファイリングおよびプロファイルの保存 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11635354B2 (ja) |
EP (1) | EP3161147B1 (ja) |
JP (1) | JP6866164B2 (ja) |
CN (1) | CN106460072B (ja) |
GB (1) | GB201411624D0 (ja) |
WO (1) | WO2016001006A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210358573A1 (en) * | 2020-01-23 | 2021-11-18 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6567214B2 (en) * | 1997-09-04 | 2003-05-20 | Andrew E. Lorincz | Microscope slide having culture media and method for use |
US6969615B2 (en) * | 1999-07-26 | 2005-11-29 | 20/20 Genesystems, Inc. | Methods, devices, arrays and kits for detecting and analyzing biomolecules |
CA2428441A1 (en) * | 2000-11-20 | 2002-06-20 | 20/20 Genesystems, Inc. | Methods, devices, arrays and kits for detecting and analyzing biomolecules |
JP2007175046A (ja) * | 2006-03-10 | 2007-07-12 | Fujitsu Ltd | インジェクション装置およびインジェクション方法 |
EP2391725A4 (en) * | 2009-01-30 | 2013-01-02 | Us Health | METHOD AND SYSTEMS FOR CLEANING TRANSMITTING AND / OR MANIPULATING NUCLEIC ACIDS |
JP5447265B2 (ja) * | 2010-07-30 | 2014-03-19 | ソニー株式会社 | マイクロビーズ自動識別方法 |
GB201106254D0 (en) * | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
US20150252356A1 (en) | 2012-08-28 | 2015-09-10 | Bio Cube System Co., Ltd. | Porous solid phase for rapidly isolating biological molecules for nucleic acid amplification reaction from biological sample, and use thereof |
US9593365B2 (en) | 2012-10-17 | 2017-03-14 | Spatial Transcriptions Ab | Methods and product for optimising localised or spatial detection of gene expression in a tissue sample |
WO2014072354A1 (en) * | 2012-11-09 | 2014-05-15 | Ge Healthcare Uk Limited | Methods for one step nucleic acid amplification of non-eluted samples |
-
2014
- 2014-06-30 GB GBGB1411624.8A patent/GB201411624D0/en not_active Ceased
-
2015
- 2015-06-23 US US15/318,297 patent/US11635354B2/en active Active
- 2015-06-23 EP EP15731561.5A patent/EP3161147B1/en active Active
- 2015-06-23 WO PCT/EP2015/064037 patent/WO2016001006A1/en active Application Filing
- 2015-06-23 JP JP2016575441A patent/JP6866164B2/ja active Active
- 2015-06-23 CN CN201580035647.0A patent/CN106460072B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
WO2016001006A1 (en) | 2016-01-07 |
US20170131188A1 (en) | 2017-05-11 |
CN106460072B (zh) | 2022-08-02 |
EP3161147B1 (en) | 2019-08-07 |
JP2017521065A (ja) | 2017-08-03 |
CN106460072A (zh) | 2017-02-22 |
EP3161147A1 (en) | 2017-05-03 |
GB201411624D0 (en) | 2014-08-13 |
US11635354B2 (en) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Janiszewska et al. | In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer | |
Ascierto et al. | Preanalytic variables and tissue stewardship for reliable next-generation sequencing (NGS) clinical analysis | |
Erickson et al. | Quantitative RT-PCR gene expression analysis of laser microdissected tissue samples | |
Jung et al. | Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma | |
JP2012517241A5 (ja) | ||
Wang et al. | Quantitative ultrasensitive bright-field RNA in situ hybridization with RNAscope | |
US20180031575A1 (en) | Detecting Dementia and Alzheimer's Disease Associated Biomarkers Stabilized on Solid Support Materials | |
Carlsson et al. | Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies | |
Kidd et al. | High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity | |
Donovan et al. | Predicting high-risk disease using tissue biomarkers | |
Piton et al. | Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma | |
US10088482B2 (en) | Prognosis of oesophageal and gastro-oesophageal junctional cancer | |
Schuster et al. | MicroRNA expression profiling of specific cells in complex archival tissue stained by immunohistochemistry | |
JP6866164B2 (ja) | 固形生体腫瘤の空間的分子プロファイリングおよびプロファイルの保存 | |
Pentheroudakis et al. | Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG) | |
Ahn et al. | A nCounter CNV assay to detect HER2 amplification: a correlation study with immunohistochemistry and in situ hybridization in advanced gastric cancer | |
Gould et al. | Chromogenic in situ hybridization methods for microRNA biomarker monitoring of drug safety and efficacy | |
JP6345610B2 (ja) | インサイツハイブリダイゼーションを使用した生物学試料の遺伝子コピー数のスコアリング法 | |
CN111278844B (zh) | 用于使用氧化铁颗粒提取核酸的方法和组合物 | |
Oh et al. | Development of an ammonium sulfate DNA extraction method for obtaining amplifiable DNA in a small number of cells and its application to clinical specimens | |
Basu et al. | Novel omics technology driving translational research in precision oncology | |
Prince et al. | Tissue‐preserving approach to extracting DNA from paraffin‐embedded specimens using tissue microarray technology | |
Armani et al. | 2D-PCR: a method of mapping DNA in tissue sections | |
Ahmed et al. | Quantification of microRNAs by absolute Dpcr for the diagnostic screening of colon cancer | |
Pallier et al. | DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180614 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20190521 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190723 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200623 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200817 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20201207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201215 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201215 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210121 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210308 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210407 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6866164 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |